Table 2 summarizes the major clinical trials of gene therapy approaches in AD and related dementias, highlighting the use of CRISPR/Cas9 and AAV vectors for therapeutic targets such as NGF, BDNF, human telomerase reverse transcriptase, and progranulin. The gene discussed is BDNF; the disease is Alzheimer disease.